Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

HAYWARD, Calif., Jan. 12 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that it has completed enrollment in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib (A-002) when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"With the varespladib trial fully enrolled, we look forward to reporting the biomarker results and event trends later this year," said Colin Hislop, M.D., Senior Vice President of Clinical Development at Anthera Pharmaceuticals, Inc. "Based upon the positive results from varespladib's two previous Phase II clinical trials that demonstrated lipid-lowering and anti- inflammatory benefits, we look forward to examining the impact of varespladib on the hyper-inflammatory state presented by ACS patients."

Anthera's FRANCIS trial is based upon direct feedback from FDA via the Special Protocol Assessment procedure. The trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. Anthera plans to enroll between 500-700 patients that will be treated for up to six months. The study is being conducted at sites across North America and Europe. The FRANCIS trial is expected to provide further insight into the prevention of secondary Major
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: the ... expertly narrows down the mass of product choices to ... , First, select the working environment, then enter ... and define the accuracy – it’s really that simple. ... list to models that fit best with the customer’s ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
...  Today, the Global Probiotics Council (GPC), a committee formed ... launch of the fifth annual Young Investigator Grant for ... in the amount of $50,000, to promising young researchers. ... the role of probiotics and gastrointestinal microbiota in health ...
... Arcion Therapeutics, a clinical stage biotechnology company developing ... received notice of allowance for a US Patent for ... ARC-2022 is being developed by Arcion for pain associated ... has been evaluated in a single-dose Phase 1 pharmacokinetic ...
... Jan. 4, 2012  Verify Brand™ announces the release ... 4.0 software. VB Enterprise 4.0 is a suite ... client and mobile software applications that enable comprehensive ... Trace® across the supply chain. VB Enterprise ...
Cached Biology Technology:Fifth Cycle of Probiotics & Microbiota Research Grant Announced 2Fifth Cycle of Probiotics & Microbiota Research Grant Announced 3Fifth Cycle of Probiotics & Microbiota Research Grant Announced 4Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain 2Verify Brand™ Announces the Release of VB Enterprise 4.0 2
(Date:7/24/2014)... electric cars ply silent freeways, solar panels blanket rooftops ... earth, from howling winds and from the blazing desert ... is technically and economically feasible to convert California,s all-purpose ... Published in Energy , the plan shows the ... in California that could create tens of thousands of ...
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... low vision specialist at The University of Texas Health ... awarded a grant to help Harris County residents whose ... surgery. , Even with corrective lenses, many people with ... are a variety of low vision devices, such as ... vision loss. , Iyer is using the three-year, $164,645 ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... turned off or left on in healthy ... common cancers and maybe help avoid them, Medical College ... alterations, called DNA methylation, in the body,s basic building ... and their cancerous counterpart to find telltale patterns that ...
... A new study finds that most older long-term cancer survivors ... health habits. The study also reveals that those survivors ... health and quality of life. Published in the September 1, ... the American Cancer Society, the research indicates that greater efforts ...
... The results of a national assessment of indoor location ... announced at Worcester Polytechnic Institute (WPI) during the 2009 ... Emergency Responders, which runs from Aug. 3 to 4. ... with funding from the Department of Homeland Security and ...
Cached Biology News:Cancer's distinctive pattern of gene expression could aid early screening and prevention 2Cancer's distinctive pattern of gene expression could aid early screening and prevention 3Cancer's distinctive pattern of gene expression could aid early screening and prevention 4Most older long-term cancer survivors have poor health habits 2Results of national assessment of first responder location systems to be announced Aug. 3 2Results of national assessment of first responder location systems to be announced Aug. 3 3Results of national assessment of first responder location systems to be announced Aug. 3 4
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
... The LXQ linear ion trap mass spectrometer ... analytical laboratory., The LXQ linear ion trap ... and proteomic applications, delivering the fast cycle ... linear ion trap at an attractive price. ...
... scientists who do not have access to microarray ... their biological samples tested for the concentration of ... 1-2-3 Chose the analytes you wish ... S&S antibody menu. Send your samples to ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Biology Products: